Last reviewed 2026-04-20 · How we verify

Avalide

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: FETAL TOXICITY When pregnancy is detected, discontinue AVALIDE as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue AVALIDE as soon as p

Common side effects

• Fatigue
• Dizziness
• Musculoskeletal pain
• Nausea
• Headache
• Sinus abnormality
• Cough
• Upper respiratory infection
• Pharyngitis
• Diarrhea
• Rhinitis
• Urinary tract infection

Serious adverse events

• Myocardial infarction
• Angina pectoris
• Syncope
• Cardiorespiratory arrest
• Heart failure
• Hypertensive crisis
• Cerebrovascular accident
• Aplastic anemia
• Pancreatitis
• Agranulocytosis

Key clinical trials

• Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.
• Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions (NA)
• Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions (NA)
• Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients (PHASE3)
• I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy (PHASE4)
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension (PHASE3)
• Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension (PHASE3)
• I PREVENT - Irbesartan In Hypertensive Diabetic Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.